Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: John who wrote (2452)	2/5/1999 8:33:00 PM
From: Abuckatatime	Read Replies (1) \| Respond to of 4676

Isis files S3. Excerpts: The net proceeds to be received by the Company from the sale of the 4,000,000 shares of Common Stock being offered hereby are estimated to be $50,900,000 assuming a public offering price of $12.75 per share and after deducting estimated offering expenses. The Company intends to use the net proceeds of this offering for its research, drug discovery and development programs and for other general corporate purposes. Expenses to be funded with the offering proceeds include costs of preclinical and clinical studies, the production of compounds for such studies and capital expenditures. The Common Stock is being offered to a limited number of investors directly by the Company. The price of the Common Stock offered hereby will be determined through negotiations between the Company and the purchasers. Common Stock outstanding after the offering = 31,147,000 shares(1) 1) Based on shares outstanding as of January 31, 1999. Does not include 7,606,730 shares of Common Stock issuable upon exercise of outstanding options or 1,248,001 shares of Common Stock issuable upon exercise of outstanding warrants as of January 31, 1999. freeedgar.com